ArticleCancers2023

Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study.

Antonio Llombart-Cussac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.